Clinical Trials
18 trialsNCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT01769222 2024-01-24
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
Phase 1 Terminated
NCT03947255 2023-10-13
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02440685 2023-06-07
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Phase 1/2 Terminated
NCT02314247 2023-01-26
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02535247 2022-07-08
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01420679 2021-11-19
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT01678443 2021-04-02
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT01408043 2019-06-14
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase NA Terminated
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00274651 2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2 Terminated
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated